This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Investigations

Authoring team

The diagnosis of Duchenne's muscular dystrophy is suggested by the finding of serum creatine kinase 30 to 200 times higher than normal, myopathic changes on electromyography and characteristic findings on muscle biopsy. Note that the serum creatine kinase is raised before the muscular weakness becomes clinically evident.

Note that the serum creatinine is also slightly raised in female carriers.

It is possible to do chromosomal analysis of the deleted part of the genome - chromosome Xp21 - and get a genetic confirmation of the disease

  • approximately 70% of DMD cases are caused by a single or multi-exon deletion or duplication detectable by multiplex ligation dependent probe amplification (MLPA)
    • full sequencing of the dystrophin gene can detect small genetic changes, such as point mutations, when DMD is still suspected but MLPA has failed to identify an abnormality

Notes:

  • a mildly raised creatine kinase level of 1-2 times the normal range should be confirmed through a repeated test and followed up
    • a normal creatine kinase result excludes DMD - however not all neuromuscular conditions are associated with elevated creatine kinase (2)
      • guidance suggests that if you suspect a muscle problem but creatine kinase levels are within the normal range, a referral to a neuromuscular specialist may still be warranted

Reference:


Create an account to add page annotations

Add information to this page that would be handy to have on hand during a consultation, such as a web address or phone number. This information will always be displayed when you visit this page

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.